Merck CEO Rob Davis

Mer­ck emerges as lead bid­der in po­ten­tial Ac­celeron buy­out with deal pos­si­ble this week — re­port

With ru­mors swirling about a po­ten­tial buy­out of biotech Ac­celeron and its lead PAH drug so­tater­cept, mar­ket watch­ers have been keep­ing close tabs on in­dus­try …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.